Cargando…
Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass
Background. Cardiopulmonary bypass surgery (CPBS) is associated with an increased risk for infections or with subsequent organ dysfunction. As T cell activation is a central mechanism during inflammatory processes, we developed an assay to evaluate T cell activation pathways in patients undergoing C...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208496/ https://www.ncbi.nlm.nih.gov/pubmed/25379560 http://dx.doi.org/10.1155/2014/801643 |
_version_ | 1782341142128361472 |
---|---|
author | Dieterlen, Maja-Theresa Bittner, Hartmuth B. Tarnok, Attila Garbade, Jens Dhein, Stefan Mohr, Friedrich W. Barten, Markus J. |
author_facet | Dieterlen, Maja-Theresa Bittner, Hartmuth B. Tarnok, Attila Garbade, Jens Dhein, Stefan Mohr, Friedrich W. Barten, Markus J. |
author_sort | Dieterlen, Maja-Theresa |
collection | PubMed |
description | Background. Cardiopulmonary bypass surgery (CPBS) is associated with an increased risk for infections or with subsequent organ dysfunction. As T cell activation is a central mechanism during inflammatory processes, we developed an assay to evaluate T cell activation pathways in patients undergoing CPBS. Methods. Blood was obtained from eleven patients undergoing CPBS preoperatively, on postoperative day (POD)-3, and on POD-7 and was stimulated with different concentrations of Concanavalin A (ConA). Cyclosporine and sirolimus, inhibiting different pathways of the T cell cycle, were added to blood ex vivo. Expression of T cell activation markers CD25 and CD95 was analyzed by flow cytometry. Results. In untreated blood, expression of CD25 and CD95 significantly increased with higher ConA concentrations (P < 0.05) and decreased for all ConA concentrations for both antigens over the study time (P < 0.05). Independently from the ConA concentration, inhibition of CD25 and CD95 expression was highest preoperatively for sirolimus and on POD-3 for cyclosporine. At all time points, inhibition of CD25 and CD95 expression was significantly higher after cyclosporine compared to sirolimus treatment (P < 0.001). Conclusion. Our results showed that different pathways of T cell activation are impaired after CPBS. Such knowledge may offer the opportunity to identify patients at risk for postoperative complications. |
format | Online Article Text |
id | pubmed-4208496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-42084962014-11-06 Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass Dieterlen, Maja-Theresa Bittner, Hartmuth B. Tarnok, Attila Garbade, Jens Dhein, Stefan Mohr, Friedrich W. Barten, Markus J. Surg Res Pract Research Article Background. Cardiopulmonary bypass surgery (CPBS) is associated with an increased risk for infections or with subsequent organ dysfunction. As T cell activation is a central mechanism during inflammatory processes, we developed an assay to evaluate T cell activation pathways in patients undergoing CPBS. Methods. Blood was obtained from eleven patients undergoing CPBS preoperatively, on postoperative day (POD)-3, and on POD-7 and was stimulated with different concentrations of Concanavalin A (ConA). Cyclosporine and sirolimus, inhibiting different pathways of the T cell cycle, were added to blood ex vivo. Expression of T cell activation markers CD25 and CD95 was analyzed by flow cytometry. Results. In untreated blood, expression of CD25 and CD95 significantly increased with higher ConA concentrations (P < 0.05) and decreased for all ConA concentrations for both antigens over the study time (P < 0.05). Independently from the ConA concentration, inhibition of CD25 and CD95 expression was highest preoperatively for sirolimus and on POD-3 for cyclosporine. At all time points, inhibition of CD25 and CD95 expression was significantly higher after cyclosporine compared to sirolimus treatment (P < 0.001). Conclusion. Our results showed that different pathways of T cell activation are impaired after CPBS. Such knowledge may offer the opportunity to identify patients at risk for postoperative complications. Hindawi Publishing Corporation 2014 2014-02-06 /pmc/articles/PMC4208496/ /pubmed/25379560 http://dx.doi.org/10.1155/2014/801643 Text en Copyright © 2014 Maja-Theresa Dieterlen et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Dieterlen, Maja-Theresa Bittner, Hartmuth B. Tarnok, Attila Garbade, Jens Dhein, Stefan Mohr, Friedrich W. Barten, Markus J. Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass |
title | Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass |
title_full | Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass |
title_fullStr | Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass |
title_full_unstemmed | Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass |
title_short | Flow Cytometric Evaluation of T Cell Activation Markers after Cardiopulmonary Bypass |
title_sort | flow cytometric evaluation of t cell activation markers after cardiopulmonary bypass |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208496/ https://www.ncbi.nlm.nih.gov/pubmed/25379560 http://dx.doi.org/10.1155/2014/801643 |
work_keys_str_mv | AT dieterlenmajatheresa flowcytometricevaluationoftcellactivationmarkersaftercardiopulmonarybypass AT bittnerhartmuthb flowcytometricevaluationoftcellactivationmarkersaftercardiopulmonarybypass AT tarnokattila flowcytometricevaluationoftcellactivationmarkersaftercardiopulmonarybypass AT garbadejens flowcytometricevaluationoftcellactivationmarkersaftercardiopulmonarybypass AT dheinstefan flowcytometricevaluationoftcellactivationmarkersaftercardiopulmonarybypass AT mohrfriedrichw flowcytometricevaluationoftcellactivationmarkersaftercardiopulmonarybypass AT bartenmarkusj flowcytometricevaluationoftcellactivationmarkersaftercardiopulmonarybypass |